The Novo Nordisk Foundation started a dialog with Novo’s board “on the merits of an accelerated CEO succession,” Novo said, ...

Danish maker of obesity drugs to replace Lars Fruergaard Jørgensen, saying new leadership is needed as shares slump 50% in ...

In an abrupt and surprising twist, the CEO of Ozempic-maker Novo Nordisk has been ousted from his position as the head of the ...

It’s the end of an era at Novo Nordisk as longtime CEO Lars Fruergaard Jørgensen—who recently shepherded the company through ...

Lars Fruergaard Jørgensen will step down after eight years helming the Danish drugmaker, shares of which have shed half their ...

The boss of the drugs giant behind Ozempic has quit after falling behind in the global race to develop weight-loss medication ...

Jørgensen will step down after eight years as CEO, with a successor search underway while the company reaffirms confidence in ...

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said Friday ...

Lars Fruergaard Jørgensen is stepping down as Novo Nordisk CEO, with the company citing its stock's recent struggles.

The boss of Ozempic maker Novo Nordisk lost his job yesterday after its share price plunged amid intensifying competition in ...

Wegovy and Ozempic-maker Novo Nordisk said today its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing its first-mover advantage in the highly competitive obesity drug ...

Heavyweight healthcare shares were the biggest boosts, jumping 1.2 per cent, boosted by AstraZeneca and Novartis. But Novo ...